Antimicrobial susceptibilities of Clostridium difficile isolated in Japan

被引:12
|
作者
Kunishima, Hiroyuki [1 ,2 ,3 ]
Chiba, Junichi [2 ]
Saito, Michiko [1 ]
Honda, Yoshihiro [2 ]
Kaku, Mitsuo [1 ]
机构
[1] Tohoku Univ, Dept Infect Control & Lab Diagnost, Grad Sch Med, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Sendai Kosei Hosp, Infect Control Team, Aoba Ku, Sendai, Miyagi 9800873, Japan
[3] Tohoku Univ, Dept Reg Cooperat Infect Dis, Grad Sch, Aoba Ku, Sendai, Miyagi 9808574, Japan
关键词
Clostridium difficile; Metronidazole; Vancomycin; Antibiotic susceptibility; Japan; IN-VITRO ACTIVITY; METRONIDAZOLE; RESISTANCE; STRAINS; OPT-80; VANCOMYCIN; AGENTS;
D O I
10.1007/s10156-013-0553-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Clostridium difficile is a common causative organism of antimicrobial-associated diarrhea and is often responsible for nosocomial infection. C. difficile infection has traditionally been treated with metronidazole (MNZ) or vancomycin (VCM); however, MNZ-resistant strains have reported in some countries. In this study the broth microdilution method was used to determine the minimum inhibitory concentrations (MICs) of 15 drugs against 157 clinical isolates of C. difficile in Japan. All C. difficile isolates tested were susceptible to MNZ; MIC50 was 0.25 mu g/ml, MIC90 was 0.5 mu g/ml, and MIC range was 0.06-1 mu g/ml. C. difficile isolates were also susceptible to VCM; MIC50 was 0.5 mu g/ml, MIC90 was 1 mu g/ml, and MIC range was 0.12-2 mu g/ml. Susceptibility to teicoplanin was also similar: MIC50 was 0.12 mu g/ml, MIC90 was 0.12 mu g/ml, and MIC range was 0.03-0.25 mu g/ml. The susceptibility of C. difficile isolates must be monitored continuously because a strain with reduced susceptibility to MNZ or VCM might emerge in the future.
引用
收藏
页码:360 / 362
页数:3
相关论文
共 50 条
  • [41] Treatment of Clostridium difficile infection
    Stroehlein J.R.
    Current Treatment Options in Gastroenterology, 2004, 7 (3) : 235 - 239
  • [42] Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel
    Bishara, J
    Bloch, Y
    Garty, M
    Behor, J
    Samra, Z
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 54 (02) : 141 - 144
  • [43] Effect of an antimicrobial stewardship intervention on outcomes for patients with Clostridium difficile infection
    Welch, Hanna K.
    Nagel, Jerod L.
    Patel, Twisha S.
    Gandhi, Tejal N.
    Chen, Benrong
    De Leon, John
    Chenoweth, Carol E.
    Washer, Laraine L.
    Rao, Krishna
    Eschenauer, Gregory A.
    AMERICAN JOURNAL OF INFECTION CONTROL, 2016, 44 (12) : 1539 - 1543
  • [44] Antimicrobial Susceptibilities of Clostridium difficile Isolates from 12 Asia-Pacific Countries in 2014 and 2015
    Lew, Tanya
    Putsathit, Papanin
    Sohn, Kyung Mok
    Wu, Yuan
    Ouchi, Kentaro
    Ishii, Yoshikazu
    Tateda, Kazuhiro
    Riley, Thomas, V
    Collins, Deirdre A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (07)
  • [45] Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection
    Paknikar, Raghavendra
    Pekow, Joel
    SURGICAL INFECTIONS, 2018, 19 (08) : 785 - 791
  • [46] Fidaxomicin: A Macrocyclic Antibiotic for the Management of Clostridium difficile Infection
    Sullivan, Karyn M.
    Spooner, Linda M.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (02) : 352 - 359
  • [47] Clostridium difficile:: Recent epidemiologic findings and advances in therapy
    McMaster-Baxter, Nicole L.
    Musher, Daniel M.
    PHARMACOTHERAPY, 2007, 27 (07): : 1029 - 1039
  • [48] Fidaxomicin: A Macrocyclic Antibiotic for the Treatment of Clostridium difficile Infection
    Hardesty, Jennifer S.
    Juang, Paul
    PHARMACOTHERAPY, 2011, 31 (09): : 877 - 886
  • [49] SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model
    Baines, S. D.
    Crowther, G. S.
    Freeman, J.
    Todhunter, S.
    Vickers, R.
    Wilcox, M. H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (01) : 182 - 189
  • [50] Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment
    James, Garth A.
    Chesnel, Laurent
    Boegli, Laura
    Pulcini, Elinor deLancey
    Fisher, Steve
    Stewart, Philip S.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (01) : 102 - 108